drugset
drugset / Trial / NCT07200986

Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects

NCT07200986 ↗

Phase 1 Active not recruiting 218 enrolled Celltrion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to demonstrate PK similarity of the proposed biosimilar test product CT-P52 and the reference product, US-licensed Taltz.

Timeline

Start
2025-09-17
Primary completion
2026-03-31
Completion
2026-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixekizumab Monoclonal antibody 80 mg Subcutaneous

Indications

No indication recorded.